Oscar Health (NYSE:OSCR) Posts Earnings Results, Beats Estimates By $0.70 EPS

Oscar Health (NYSE:OSCR) announced its earnings results on Thursday. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.70, FiscalAI reports. The company had revenue of $4.88 billion for the quarter, compared to analyst estimates of $4.73 billion. Oscar Health had a return on equity of 44.96% and a net margin of 3.60%.The firm’s quarterly revenue was up 70.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.89) earnings per share.

Here are the key takeaways from Oscar Health’s conference call:

• Strong profitability and raised outlook: Oscar reported $1.1 billion in first-half earnings from operations and $1 billion in net income. Management raised full-year earnings-from-operations guidance by $250 million to $500 million–$700 million while maintaining its revenue outlook.
• Membership and operating metrics improved materially: Effectuated membership increased 46% year over year to 2.96 million, revenue rose 70% to $4.9 billion, and second-quarter MLR improved nearly 12 points to 79.2%. The SG&A ratio fell 450 basis points to a record-low 14.2%.
• Favorable medical trends provide potential upside: Inpatient, professional, and pharmacy utilization were favorable, while outpatient utilization was elevated but stable. Early 2026 morbidity data was better than pricing assumptions, although Oscar has not fully reflected that potential benefit in its guidance.
• Technology and AI are driving efficiency: Oscar said its AI-enabled claims, pharmacy, care-navigation, and member-support tools are reducing costs and improving productivity. The company expects its pharmacy analytics and related initiatives to generate tens of millions of dollars in annual savings and sees additional SG&A leverage ahead.
• Enrollment churn is expected to increase in the second half: CMS eligibility and program-integrity reviews are expected to produce disenrollments that were delayed from the second quarter, with churn potentially approaching twice the previously expected 1%–2% monthly rate. Management said the financial impact is included in guidance and primarily reflects timing rather than a fundamental change in retention.

Oscar Health Trading Up 5.2%

Shares of Oscar Health stock traded up $1.39 on Friday, hitting $27.93. The stock had a trading volume of 10,468,402 shares, compared to its average volume of 4,846,594. The stock has a 50 day moving average of $28.93 and a 200 day moving average of $20.37. The firm has a market capitalization of $8.42 billion, a P/E ratio of 19.95, a PEG ratio of 1.35 and a beta of 2.36. Oscar Health has a twelve month low of $10.69 and a twelve month high of $33.10. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.11 and a current ratio of 1.11.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on OSCR shares. Wolfe Research initiated coverage on Oscar Health in a report on Tuesday, May 5th. They set a “peer perform” rating for the company. Jefferies Financial Group raised shares of Oscar Health from an “underperform” rating to a “hold” rating and raised their target price for the stock from $10.00 to $16.00 in a report on Monday, April 20th. UBS Group lifted their price target on shares of Oscar Health from $20.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday. Zacks Research upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. Finally, Robert W. Baird set a $27.00 price target on Oscar Health in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.00.

Insider Activity

In other Oscar Health news, CEO Mark T. Bertolini sold 624,244 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $28.48, for a total value of $17,778,469.12. Following the completion of the transaction, the chief executive officer directly owned 7,751,570 shares in the company, valued at approximately $220,764,713.60. This represents a 7.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Janet Liang sold 12,475 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total transaction of $273,701.50. Following the completion of the transaction, the insider owned 259,057 shares of the company’s stock, valued at approximately $5,683,710.58. This trade represents a 4.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 3,662,466 shares of company stock worth $105,145,815. Company insiders own 22.64% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OSCR. T. Rowe Price Investment Management Inc. grew its position in shares of Oscar Health by 11.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock valued at $132,461,000 after buying an additional 910,320 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Oscar Health by 14.4% in the fourth quarter. Invesco Ltd. now owns 303,434 shares of the company’s stock worth $4,360,000 after acquiring an additional 38,163 shares during the period. XTX Topco Ltd lifted its stake in shares of Oscar Health by 16.0% in the fourth quarter. XTX Topco Ltd now owns 107,854 shares of the company’s stock worth $1,550,000 after acquiring an additional 14,865 shares during the period. VARCOV Co. bought a new stake in Oscar Health in the fourth quarter valued at approximately $688,000. Finally, Wellington Management Group LLP increased its position in Oscar Health by 4.1% during the 4th quarter. Wellington Management Group LLP now owns 374,015 shares of the company’s stock valued at $5,375,000 after purchasing an additional 14,590 shares during the period. 75.70% of the stock is owned by institutional investors.

Oscar Health News Roundup

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Substantial earnings and revenue beat: Oscar reported quarterly EPS of $1.10, versus the $0.40–$0.43 analyst consensus, compared with a $0.89 loss in the year-ago quarter. Revenue rose 70.4% to $4.88 billion, exceeding estimates of approximately $4.73 billion. Oscar Health Inc. Q2 Earnings Beat Estimates
• Positive Sentiment: Profitability improved sharply: The insurer generated approximately $361 million of second-quarter profit and more than $1 billion in net income during the first half, helped by membership growth and easing medical costs. Oscar Health Reports Another Big Profit
• Positive Sentiment: Full-year outlook was raised: Oscar increased its 2026 revenue forecast to $18.7 billion–$19.0 billion, above the roughly $18.6 billion consensus estimate, and indicated $500 million–$700 million in earnings from operations with an 81.5%–82.5% medical-loss-ratio target. Oscar Health Signals 2026 Earnings Outlook
• Neutral Sentiment: The results reinforce Oscar’s improving profit-turnaround story, with technology and operational execution remaining important to managing a changing customer base. Oscar Health 2026 Profit Turnaround
• Negative Sentiment: Churn outlook pressured the shares: Management’s forecast for elevated member churn raised concerns about retention, future enrollment growth and whether the unusually strong earnings can be sustained. That concern reportedly outweighed the quarterly beat and guidance increase. Oscar Health Falls as Churn Forecast Overshadows Q2 Beat

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.